Annexon Spotlights GA Phase III, GBS Regulatory Plans and ANX1502 Update at TD Cowen Conference [Yahoo! Finance]
Annexon, Inc. - common stock (ANNX)
Company Research
Source: Yahoo! Finance
chat at TD Cowen's 46th Annual Healthcare Conference, with President and CEO Douglas Love emphasizing upcoming clinical catalysts, ongoing regulatory work, and preparations for potential commercialization. Company focus and pipeline priorities Love said Annexon is pursuing a “next-generation neuroinflammatory approach” focused on inhibiting the classical pathway, which he described as providing “the most complete protection against complement, classical complement-driven inflammation.” He outlined two late-stage programs—geographic atrophy (GA) and Guillain-Barré syndrome (GBS)—and a third program built around a first-in-kind oral small molecule candidate, ANX1502. ? Defense Stocks Are Soaring—AeroVironment's Earnings Could Close the Gap Love characterized Annexon's strategy as non–“me-too,” arguing the company is trying to change treatment expectations in its targeted diseases. He also noted that being first can require overcoming entrenched assumptions, citing GBS as an area
Show less
Read more
Impact Snapshot
Event Time:
ANNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANNX alerts
High impacting Annexon, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
ANNX
News
- Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care ConferenceGlobeNewswire
- Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy [Yahoo! Finance]Yahoo! Finance
- Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic AtrophyGlobeNewswire
- Annexon Offers A High-Risk, High-Reward Play On A New Approach To Complement-Mediated Diseases [Seeking Alpha]Seeking Alpha
- Annexon (NASDAQ:ANNX) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
ANNX
Earnings
- 11/10/25 - Miss
ANNX
Sec Filings
- 3/4/26 - Form 4
- 3/4/26 - Form 4
- 3/4/26 - Form 4
- ANNX's page on the SEC website